An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer

Published:2016-02-06 Issue:4 Volume:17 Page:346-354
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Li Hongwen,Yu Chao,Jiang Jing,Huang Changjiang,Yao Xuejing,Xu Qiaoyu,Yu Fang,Lou Liguang,Fang Jianmin

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/15384047.2016.1139248

Reference45 articles.

1. Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention

2. THE CHRONOLOGY OF EARLY EPIC - (O.) Andersen, (D.T.T.) Haug (edd.) Relative Chronology in Early Greek Epic Poetry. Pp. xiv + 277, figs. Cambridge: Cambridge University Press, 2012. Cased, £60, US$99. ISBN: 978-0-521-19497-6.

3. Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)

4. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

5. HER2 aberrations in cancer: Implications for therapy

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09

2. Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022;BMC Cancer;2024-07-26

3. An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates;Molecular Pharmaceutics;2024-07-24

4. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

5. Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study;Cancer Communications;2024-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3